Federal Register / Vol. 63, No. 102 /Thursday, May 28, 1998 / Notices 29235

be contacted by: telephone: 1–888–300-

HRSA, FAX: 301–309–0579, or e-mail:

HRSA.GAC@x.netcom.com. Completed

applications should be returned to:

Grants Management Officer (CFDA

#93.926b), HRSA Grants Application

Center, 40 West Gude Drive, Suite 100,

Rockville, Maryland 20850.

DATES: The application deadline date is

Thursday, July 1, 1998.

Dated: May 21, 1998.

Claude Earl Fox,

Administrator.

[FR Doc. 98–14091 Filed 5–27–98; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Eye Institute Special Emphasis

Panel (SEP) meeting:

Name of SEP: Clinical Research.

Date: May 27, 1998.

Time: 2:00 p.m.

Place: Telephone Conference, Executive

Plaza South, Room 350.

Contact Person: Andrew P. Mariani, Ph.D.,

Executive Plaza South, Room 350, 6120

Executive Blvd., Bethesda, MD 20892–7164,

(301) 496–5561.

Purpose/Agenda: Review of Grant

Applications.

Name of SEP: Clinical Research.

Date: May 29, 1998.

Time: 8:30 a.m.

Place: National Eye Institute, Executive

Plaza South, Room 350, 6120 Executive

Blvd., Bethesda, MD 20892–7164.

Contact Person: Andrew P. Mariani, Ph.D.,

Executive Plaza South, Room 350, 6120

Executive Blvd., Bethesda, MD 20892–7164,

(301) 496–5561.

Purpose/Agenda: Review of Grant

Applications.

These meetings will be closed in

accordance with the provisions set forth in

sections 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than

fifteen days prior to the meeting due to the

urgent need to meet timing limitations

imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance

Program No. 93.867, Vision Research:

National Institutes of Health)

Dated: May 21, 1998.

LaVerne Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14137 Filed 5–27–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel Program

Project.

Date: June 22, 1998.

Time: 8:00 am to 7:00 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Bethesda, 8120

Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: AFTAB A. ANSARI, PHD,

NIAMS, 45 CENTER DRIVE, 5AS 25U.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.846, Arthritis,

Musculoskeletal and Skin Diseases Research,

National Institutes of Health, HHS)

Dated: May 20, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14135 Filed 5–27–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Purpose/Agenda: To review and evaluate a

contract proposal.

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date of Meeting: May 21, 1998 (Telephone

Conference).

Time: 10:00 a.m.

Place of Meeting: Willco Building, Suite

400, 6000 Executive Boulevard, Rockville,

MD.

Contact Person: Sean O’Rourke, 6000

Executive Boulevard, Suite 409, Rockville,

MD 20892–7003, 301–443–2861.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

The meeting will be closed in accordance

with the provisions set forth in Sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material, and personal

information concerning individuals

associated with the applications and/or

proposals, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance,

Program Nos. 93.271, Alcohol Research

Career Development Awards for Scientists

and Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

and 93.891, Alcohol Research Center Grants;

National Institutes of Health)

Dated: May 20, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14136 Filed 5–27–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Noncompetitive Antagonists

of Dopamine Reuptake Inhibitors To

Treat Drug Addiction

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: PCT

Application Serial No. PCT/US97/

19758, entitled, ‘‘Sustained Release

Derivatives of Hydroxylated Analogs of

Substituted 1-(2-

[Bis(aryl)methoxy]ethyl)-piperazines

and -homopiperazines and Their Use as